Tagged with EY

Pharma Olivier Pilley, French GM of the Swiss-American biotech company with a pioneering computational approach to anti-cancer therapies, presents ARIAD’s fascinating R&D model, his optimistic assessment of the competitiveness of the French clinical research environment as well as his personal motivations for working in a rapidly growing biotech company. ARIAD’s niche is…

Puerto Rico With a recent investment of $35 million in a new R&D site in Puerto Rico, Honeywell Aerospace continues to demonstrate its solid commitment to the country in its key role as part of the country’s aerospace sector. Site Leader Vicente Nazario outlines the growth of this division in Puerto Rico…

pharma The managing director of Adcock Ingram’s prescription business, Ashley Pearce highlights the division’s strategic placement within the group’s overall activities, and how he plans on leveraging partnerships with various multinationals, expand into biosimilars and grow the generics business into a market leading position. Adcock Ingram has undergone several strategic changes…

pharma Pierre Banzet, President of Group Synerlab, one of the top ten French CMOs, discusses his group’s ambitious European expansion strategy, driven by their specialties in multi-dose, preservative-free eye drops, generics, medical devices and hospital markets, and uniqueness in terms of its culture of customer service. He also discusses his perspective…

Pharma Tugce Gozacan (pictured) and Okan Gozacan, Owner and Chairman of Marmara Ecza respectively, discuss what qualities are crucial for suppliers in the pharmaceutical industry, their process for forming partnerships and attracting clients, and their vision for a future with Iran as a major player. As an introduction for our readers,…

Pharma The general manager of Drogsan, Ersan Kuçuk elaborates on the company’s efforts in shifting towards more value-added pharmaceutical products, specifically within the realm of biosimilars, while highlighting his ambitions in expanding the company’s presence within OTC. He also illustrates the decision to move Drogsan’s R&D department to the Gazi University…

pharma Consumer healthcare products manufacturer Winalite is working to penetrate the Turkish market, but with regulations complicating bringing their portfolio from China, general manager Arafat Yadigar is looking to develop a Turkey specific portfolio in collaboration with the Turkish health products and pharmaceutical manufacturing sectors.  Your promotion to General Manager is…

pharma Ozgur Tomruk, J&J’s Managing Director for Global Surgery talks about Turkey’s importance for the company, the priorities they have set, J&J’s commitment to quality and his ambition for the company’s future in Turkey. As an introduction for our readers, Ozgur, can you please give an overview of where J&J Turkey…

pharma Nil Tunaşar, managing partner of Transorient, discusses significance of tracking performance metrics among 3PL providers, the organization’s technology overhaul, and also highlights the type of logistics solutions encompassed under Transorient’s Life Sciences and Biopharma line of business. As an introduction for our readers, Nil, please provide some insight into Transorient’s…

pharma Matthias Diewald (MD) and Asli Volkan (AV) elaborate on HELM Kimya’s longstanding presence within Turkey and the type of market opportunities available for co-development and contract manufacturing. They also explain the significance of establishing strong partnerships with local industry leaders and how this can effectively drive future success for the company’s…

pharma The general manager of Ali Raif, Muzaffer Bal illustrates the various success factors that allowed the company to secure market leading positions within Turkey and across Europe, while also highlighting how the company has adapted its portfolio to shifting market dynamics. Muzaffer, as an introduction for our readers, please provide…

pharma Haluk Ataoglu, academic turned founder of Matriks Biotek®, talks about his aspirations for his company and the Turkish R&D landscape as well as how to penetrate the global pharmaceutical market as a Turkish brand. As an introduction Haluk, can you tell us what your initial aspirations were in starting Matriks…